ACADIA Pharmaceuticals (ACAD) Competitors

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

Do institutionals and insiders have more ownership in ACAD or GMAB?

96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 7.1% of Genmab A/S shares are held by institutional investors. 28.3% of ACADIA Pharmaceuticals shares are held by company insiders. Comparatively, 1.5% of Genmab A/S shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Does the media refer more to ACAD or GMAB?

In the previous week, ACADIA Pharmaceuticals had 2 more articles in the media than Genmab A/S. MarketBeat recorded 11 mentions for ACADIA Pharmaceuticals and 9 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 1.01 beat ACADIA Pharmaceuticals' score of 0.81 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has higher valuation and earnings, ACAD or GMAB?

Genmab A/S has higher revenue and earnings than ACADIA Pharmaceuticals. Genmab A/S is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$996.28M	3.70	$226.45M	$1.37	16.07
Genmab A/S	$3.12B	4.35	$1.14B	$1.76	12.02

Which has more risk & volatility, ACAD or GMAB?

ACADIA Pharmaceuticals has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500.

Do analysts rate ACAD or GMAB?

ACADIA Pharmaceuticals presently has a consensus target price of $27.88, indicating a potential upside of 26.65%. Genmab A/S has a consensus target price of $37.80, indicating a potential upside of 78.72%. Given Genmab A/S's higher probable upside, analysts clearly believe Genmab A/S is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.71
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

Is ACAD or GMAB more profitable?

Genmab A/S has a net margin of 35.11% compared to ACADIA Pharmaceuticals' net margin of 22.97%. Genmab A/S's return on equity of 18.08% beat ACADIA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	22.97%	17.46%	10.75%
Genmab A/S	35.11%	18.08%	14.52%

Summary

Genmab A/S beats ACADIA Pharmaceuticals on 10 of the 16 factors compared between the two stocks.